Advertisement

Journal of Inherited Metabolic Disease

, Volume 33, Issue 1, pp 61–67 | Cite as

Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones

  • Audrey Arfi
  • Magali Richard
  • Christelle Gandolphe
  • Daniel Scherman
Original Article

Abstract

Mucopolysaccharidoses are autosomal and recessive lysosomal storage disorders caused by the deficiency of a lysosomal enzyme involved in glycosaminoglycan catabolism. The Sanfilippo type A disease (MPS III A) results from sulfamidase deficiency, which leads to accumulation of heparan sulfate, whereas Sly disease (MPS VII) results from beta-glucuronidase deficiency, leading to accumulation of heparan, dermatan, and chondroitin sulfates. These syndromes are characterized by severe central nervous system degeneration, resulting in progressive mental retardation, and fatality occurs in severely affected children. To date, no effective treatment is available except for bone marrow transplantation in specific cases. Recently, the use of genistein, an isoflavone that inhibits glycosaminoglycans synthesis, has been tested as substrate reduction therapy for neuronopathic forms of these diseases. We tested five natural analogs to genistein in human fibroblasts from both Sanfilippo A and Sly patients. Four molecules were as efficient as genistein in decreasing glycosaminoglycan accumulation. Moreover, a combination of several isoflavones was more efficient than one single isoflavone, suggesting a synergistic effect. These preliminary data may offer new perspectives for treating Sly and Sanfilippo A diseases and could be relevant to other neurological forms of mucopolysaccharidoses.

Keywords

Genistein Isoflavones Daidzein Formononetin Glycitein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbeviations

GAGs

Glycosaminoglycans

MPS

Mucopolysaccharidoses

LSD

Lysosomal storage disease

CNS

Central nervous system

ERT

Enzyme replacement therapy

SDT

Substrate deprivation therapy

SRT

Substrate reduction therapy

DMB

Dimethylmethylene blue

Notes

Acknowledgements

We thank C. Caillaud for providing human fibroblasts derived from healthy volunteers. We also thank very much G. Chabot for all his advices regarding the isoflavone selection. This work was supported by the 6th PCRDT European “CLINIGENE” Network of Excellence and the MOLEDA STREP. A.A. received sponsorship from CLINIGENE.

References

  1. Beck M (2007) New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet 121(1):1–22CrossRefPubMedGoogle Scholar
  2. Bloedon LT, Jeffcoat AR, Lopaczynski W et al (2002) Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Am J Clin Nutr 76(5):1126–1137PubMedGoogle Scholar
  3. Brooks DA, Muller VJ, Hopwood JJ (2006) Stop-codon read-through for patients affected by a lysosomal storage disorder. Trends Mol Med 12(8):367–373CrossRefPubMedGoogle Scholar
  4. Busby MG, Jeffcoat AR, Bloedon LT et al (2002) Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr 75(1):126–136PubMedGoogle Scholar
  5. Cleary MA, Wraith JE (1993) Management of mucopolysaccharidosis type III. Arch Dis Child 69:403–406CrossRefPubMedGoogle Scholar
  6. Cox TM (2005) Substrate reduction therapy for lysosomal storage diseases. Acta Paediatr Suppl 94(447):69–75CrossRefPubMedGoogle Scholar
  7. Fischer L, Mahoney C, Jeffcoat AR et al (2004) Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Nutr Cancer 48(2):160–170CrossRefPubMedGoogle Scholar
  8. Handayani R, Rice L, Cui Y et al (2006) Soy isoflavones alter expression of genes associated with cancer progression, including interleukin-8, in androgen-independent PC-3 human prostate cancer cells. J Nutr 136(1):75–82PubMedGoogle Scholar
  9. Harmatz P, Giugliani R, Schwartz I et al, MPS VI Phase 3 Study Group (2006) Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 148(4):533–539CrossRefGoogle Scholar
  10. Jakóbkiewicz-Banecka J, Wegrzyn A, Wegrzyn G (2007) Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases. J Appl Genet 48(4):383–388PubMedGoogle Scholar
  11. Jakóbkiewicz-Banecka J, Piotrowska E, Narajczyk M, Barańska S, Wegrzyn G (2009) Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J Biomed Sci 16:26CrossRefPubMedGoogle Scholar
  12. Kakkis ED, Muenzer J, Tiller GE et al (2001) Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344(3):182–188CrossRefGoogle Scholar
  13. Malinowska M, Wilkinson FL, Bennett W et al (2009) Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol Genet Metab 98(3):235–242CrossRefPubMedGoogle Scholar
  14. Michael McClain R, Wolz E, Davidovich A, Bausch J (2005) Genetic toxicity studies with genistein. Food Chem Toxicol 44(1):42–55PubMedGoogle Scholar
  15. Miltyk W, Craciunescu CN, Fischer L et al (2003) Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 77(4):875–882PubMedGoogle Scholar
  16. Muenzer J, Lamsa JC, Garcia A, Dacosta J, Garcia J, Treco DA (2002) Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl 91(439):98–99CrossRefPubMedGoogle Scholar
  17. Muenzer J, Wraith JE, Beck M et al (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8(8):465–473CrossRefPubMedGoogle Scholar
  18. Neufeld E, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3421–3452Google Scholar
  19. Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA (2001) Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 74(4):418–425PubMedGoogle Scholar
  20. Pastores GM, Sathe S (2006) A chaperone-mediated approach to enzyme enhancement as a therapeutic option for the lysosomal storage disorders. Drugs R D 7(6):339–348CrossRefPubMedGoogle Scholar
  21. Pelled D, Raveh T, Riebeling C, Fridkin M, Berissi H, Futerman AH, Kimchi A (2002) Death-associated protein (DAP) kinase plays a central role in ceramide-induced apoptosis in cultured hippocampal neurons. J Biol Chem 277(3):1957–1961CrossRefPubMedGoogle Scholar
  22. Piotrowska E, Jakóbkiewicz-Banecka J, Barańska S, Tylki-Szymańska A, Czartoryska B, Wegrzyn A, Wegrzyn G (2006) Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 14(7):846–852CrossRefPubMedGoogle Scholar
  23. Piotrowska E, Jakóbkiewicz-Banecka J, Tylki-Szymanska A, Libereck A, Maryaniak A, Malinowska M, Czartoryska B, Puk E, Kloska A, Libereck T, Barańska S, Wegrzyn A, Wegrzyn G (2008) Genistein-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo Syndrome: an open-label, pilot study in 10 pediatric patients. Curr Ther Res 69(2):166–179CrossRefGoogle Scholar
  24. Piotrowska E, Jakóbkiewicz-Banecka J, Wegrzyn G (2009) Different amounts of isoflavones in various commercially available soy extracts in the light of gene expression-targeted isoflavone therapy. Phytother Res [Epub ahead of print].Google Scholar
  25. Raman R, Raguram S, Venkataraman G, Paulson JC, Sasisekharan R (2005) Glycomics: an integrated systems approach to structure-function relationships of glycans. Nat Methods 2(11):817–824CrossRefPubMedGoogle Scholar
  26. Richard M, Arfi A, Rhinn H, Gandolphe C, Scherman D (2008) Identification of new markers for neurodegeneration process in the mouse model of Sly disease as revealed by expression profiling of selected genes. J Neurosci Res 86(15):3285–3294CrossRefPubMedGoogle Scholar
  27. Richard M, Arfi A, Seguin J, Gandolphe C, Scherman D (2009) Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery. Gene Ther 16(6):746–756CrossRefPubMedGoogle Scholar
  28. Settembre C, Fraldi A, Jahreiss L et al (2008) A block of autophagy in lysosomal storage disorders. Hum Mol Genet 17(1):119–129CrossRefPubMedGoogle Scholar
  29. Sly WS, Quinton BA, McAlister WH, Rimoin DL (1973) Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J Pediatr 82(2):249–257CrossRefPubMedGoogle Scholar
  30. Tomatsu S, Montaño AM, Ohashi A et al (2008) Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet 17(6):815–824CrossRefPubMedGoogle Scholar
  31. Tsai TH (2005) Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. J Chromatogr A 1073:317–322CrossRefPubMedGoogle Scholar
  32. Ullmann U, Oberwittle H, Grossmann M, Riegger C (2005) Repeated oral once daily intake of increasing doses of the novel synthetic genistein product Bonistein in healthy volunteers. Planta Med 71(10):891–896CrossRefPubMedGoogle Scholar
  33. Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA (2008) Sanfilippo syndrome: a mini-review. J Inherit Metabol Dis 31(2):240–252CrossRefGoogle Scholar
  34. Wraith JE (2005) The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 6(3):489–506CrossRefPubMedGoogle Scholar
  35. Wraith JE, Clarke LA, Beck M et al (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 144(5):581–588CrossRefPubMedGoogle Scholar

Copyright information

© SSIEM and Springer 2010

Authors and Affiliations

  • Audrey Arfi
    • 1
    • 2
    • 3
    • 4
    • 5
  • Magali Richard
    • 1
    • 2
    • 3
    • 4
    • 5
  • Christelle Gandolphe
    • 1
    • 2
    • 3
    • 4
    • 5
  • Daniel Scherman
    • 1
    • 2
    • 3
    • 4
    • 5
  1. 1.Inserm, U640ParisFrance
  2. 2.CNRS, UMR8151ParisFrance
  3. 3.Faculté de Pharmacie, Chemical and Genetic Pharmacology LaboratoryUniversité Paris DescartesParisFrance
  4. 4.Ecole Nationale Supérieure de Chimie de ParisParisFrance
  5. 5.CNRS UMR 8151, Inserm, U640, Faculté de PharmacieParisFrance

Personalised recommendations